The EMA's Committee for Medicinal Products for Human Use (CHMP) adopted positive opinions for five orphan drugs but rejected Sarepta’s Elevidys gene therapy for Duchenne muscular dystrophy due to insufficient efficacy evidence. The regulatory landscape continues to tighten scrutiny on treatments for rare diseases. Positive orphan approvals signal ongoing progress in incentivizing rare disease treatment development despite setbacks for contested therapies.